CDC34 and plasma cell myeloma: Accordingly, expression of a dominant-negative Cdc34 mutant enhances anti-myeloma activity of Bortezomib17 and cisplatin therapy inhibits Cdc34-mediated degradation of ATF5, a prosurvival transcription factor18, generating interest in the SCF-Cdc34 pathway as a potential therapeutic target19–21.